{"id":"erlotinib-pemetrexed","safety":{"commonSideEffects":[{"rate":"40–75%","effect":"Rash/dermatitis"},{"rate":"40–55%","effect":"Diarrhea"},{"rate":"30–50%","effect":"Nausea/vomiting"},{"rate":"25–40%","effect":"Fatigue"},{"rate":"20–40%","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"15–30%","effect":"Elevated liver enzymes"},{"rate":"1–3%","effect":"Interstitial lung disease"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Erlotinib is a small-molecule tyrosine kinase inhibitor that blocks epidermal growth factor receptor (EGFR) signaling, preventing tumor cell proliferation in EGFR-mutant or EGFR-dependent cancers. Pemetrexed is an antifolate antimetabolite that inhibits thymidylate synthase and other folate-dependent enzymes, disrupting DNA and RNA synthesis. The combination leverages complementary mechanisms to enhance cytotoxic and targeted effects in lung cancer.","oneSentence":"This combination uses erlotinib to inhibit EGFR signaling and pemetrexed to disrupt folate-dependent nucleotide synthesis, together targeting non-small cell lung cancer through dual pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:29:33.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (NSCLC), likely EGFR-mutant or advanced disease"}]},"trialDetails":[{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":218},{"nctId":"NCT04322890","phase":"PHASE2","title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2020-04-16","conditions":"Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation","enrollment":6000},{"nctId":"NCT05081674","phase":"PHASE2","title":"Brazilian Lung Immunotherapy Study","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2020-01-01","conditions":"Lung Neoplasm","enrollment":154},{"nctId":"NCT02045446","phase":"PHASE2","title":"Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-02","conditions":"Stage IV Non-Small Cell Lung Cancer","enrollment":29},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT03110484","phase":"PHASE2","title":"Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-07-09","conditions":"Biliary Tract Cancer","enrollment":44},{"nctId":"NCT03086538","phase":"PHASE2","title":"Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2017-05-30","conditions":"Colo-rectal Cancer","enrollment":29},{"nctId":"NCT01454102","phase":"PHASE1","title":"Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-16","conditions":"Non-small Cell Lung Cancer","enrollment":472},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT01178411","phase":"PHASE1, PHASE2","title":"An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2010-08-31","conditions":"Advanced Solid Tumors","enrollment":60},{"nctId":"NCT00835471","phase":"PHASE2","title":"2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Dutch Society of Physicians for Pulmonology and Tuberculosis","startDate":"2009-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":195},{"nctId":"NCT00950365","phase":"PHASE2","title":"Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2006-04","conditions":"Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma","enrollment":79},{"nctId":"NCT04455594","phase":"PHASE2","title":"Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2020-10","conditions":"Non-Small Cell Lung Cancer Stage IIIA","enrollment":168},{"nctId":"NCT04115410","phase":"","title":"PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-07-01","conditions":"Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events","enrollment":4724},{"nctId":"NCT03460678","phase":"PHASE4","title":"Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.","status":"TERMINATED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2018-02-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":9},{"nctId":"NCT02468661","phase":"PHASE1","title":"A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09-23","conditions":"Non-Small Cell Lung Cancer","enrollment":23},{"nctId":"NCT02117024","phase":"PHASE2","title":"A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Heat Biologics","startDate":"2014-07","conditions":"Non Small Cell Lung Cancer","enrollment":66},{"nctId":"NCT02723578","phase":"PHASE2","title":"Pemetrexed and Erlotinib for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2015-12-01","conditions":"Metastatic Colorectal Cancer","enrollment":50},{"nctId":"NCT01116219","phase":"PHASE2","title":"Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-06","conditions":"Lung Cancer","enrollment":149},{"nctId":"NCT01376310","phase":"PHASE2","title":"GSK1120212 Rollover Study","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-11-02","conditions":"Cancer","enrollment":159},{"nctId":"NCT00573989","phase":"PHASE1, PHASE2","title":"Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-03","conditions":"Head and Neck Cancer","enrollment":27},{"nctId":"NCT03628521","phase":"PHASE1","title":"First-line Combination Treatment Based on Anlotinib","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2018-07-20","conditions":"Lung Cancer, Advanced Stage","enrollment":80},{"nctId":"NCT01395758","phase":"PHASE2","title":"Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2011-07","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":96},{"nctId":"NCT00577707","phase":"PHASE2","title":"Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-11","conditions":"Non Small Cell Lung Cancer, Lung Cancer","enrollment":9},{"nctId":"NCT00619424","phase":"PHASE1","title":"A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-15","conditions":"Lung Cancer, Non-Small Cell","enrollment":58},{"nctId":"NCT01192165","phase":"PHASE1","title":"Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-14","conditions":"Cancer","enrollment":169},{"nctId":"NCT01344824","phase":"PHASE2","title":"Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2010-03","conditions":"Lung Cancer","enrollment":38},{"nctId":"NCT01351415","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-06-25","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":485},{"nctId":"NCT02178397","phase":"PHASE3","title":"A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR","status":"TERMINATED","sponsor":"Centre Francois Baclesse","startDate":"2014-06","conditions":"NSCLC Patients With EGFR Activating Mutation","enrollment":6},{"nctId":"NCT02064491","phase":"PHASE2","title":"Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC","status":"COMPLETED","sponsor":"Finnish Lung Cancer Group","startDate":"2014-02","conditions":"Non-small Cell Lung Cancer","enrollment":18},{"nctId":"NCT00351039","phase":"PHASE1, PHASE2","title":"Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2006-07","conditions":"Non-Small Cell Lung Cancer","enrollment":8},{"nctId":"NCT00775385","phase":"PHASE2, PHASE3","title":"TAilored Post-Surgical Therapy in Early Stage NSCLC","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2009-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":152},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT02795884","phase":"PHASE3","title":"Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation","status":"WITHDRAWN","sponsor":"Yonsei University","startDate":"2016-06","conditions":"NSCLC","enrollment":""},{"nctId":"NCT02886195","phase":"PHASE3","title":"EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2016-07","conditions":"EGFR Gene Mutation","enrollment":120},{"nctId":"NCT02031601","phase":"PHASE4","title":"Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2014-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":250},{"nctId":"NCT02701231","phase":"NA","title":"Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2015-11","conditions":"Lung Neoplasms","enrollment":200},{"nctId":"NCT02037997","phase":"PHASE2","title":"Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2013-12","conditions":"Non Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT01664533","phase":"","title":"An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":57},{"nctId":"NCT00738881","phase":"PHASE3","title":"Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-10","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer","enrollment":23},{"nctId":"NCT00660816","phase":"PHASE2","title":"Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2008-01","conditions":"Lung Cancer","enrollment":46},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT01204307","phase":"PHASE2","title":"Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2010-01","conditions":"Advanced Non-Squamous Non-Small Cell Lung Cancer","enrollment":101},{"nctId":"NCT01928160","phase":"PHASE2","title":"Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib","status":"WITHDRAWN","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2014-06","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02399566","phase":"PHASE4","title":"Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"Hunan Province Tumor Hospital","startDate":"2015-05","conditions":"Lung Adenocarcinoma","enrollment":300},{"nctId":"NCT00556322","phase":"PHASE3","title":"A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer","enrollment":424},{"nctId":"NCT01578668","phase":"PHASE2","title":"Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases","status":"COMPLETED","sponsor":"Guangzhou Medical University","startDate":"2012-01","conditions":"Lung Adenocarcinoma, Brain Metastases","enrollment":69},{"nctId":"NCT01565538","phase":"PHASE2","title":"Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma","status":"COMPLETED","sponsor":"Si-Yu Wang","startDate":"2008-12","conditions":"Lung Cancer","enrollment":123},{"nctId":"NCT02066038","phase":"PHASE2","title":"Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-01","conditions":"Lung, Carcinoma","enrollment":60},{"nctId":"NCT00989690","phase":"PHASE3","title":"Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Istituto Scientifico H. San Raffaele","startDate":"2008-02","conditions":"Lung Cancer","enrollment":275},{"nctId":"NCT00550173","phase":"PHASE2","title":"A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-11","conditions":"Non-Small-Cell Lung Cancer","enrollment":247},{"nctId":"NCT00320073","phase":"PHASE1","title":"Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-08","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":41},{"nctId":"NCT00447057","phase":"PHASE2","title":"Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-03","conditions":"Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.","enrollment":204},{"nctId":"NCT00440414","phase":"PHASE3","title":"Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2006-04","conditions":"Non Small Cell Lung Cancer","enrollment":320},{"nctId":"NCT00387322","phase":"PHASE1, PHASE2","title":"Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2005-03","conditions":"Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":42},{"nctId":"NCT00903292","phase":"NA","title":"Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2009-03","conditions":"Non-Small Cell Lung Cancer","enrollment":52},{"nctId":"NCT00095225","phase":"PHASE2","title":"A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2004-07","conditions":"Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local","enrollment":122}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Erlotinib, Pemetrexed","genericName":"Erlotinib, Pemetrexed","companyName":"Hunan Province Tumor Hospital","companyId":"hunan-province-tumor-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erlotinib is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) and is used to treat advanced non-small-cell lung cancer. Pemetrexed is used to treat advanced non-squamous non-small cell lung cancer, but its exact mechanism is not specified in the provided facts.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}